✦ LIBER ✦

Relationship Between Level of Hepatitis B Virus DNA and Liver Disease: A Population-based Study of Hepatitis B e Antigen–Negative Persons With Hepatitis B

✍ Scribed by McMahon, Brian J.; Bulkow, Lisa; Simons, Brenna; Zhang, Yuhong; Negus, Susan; Homan, Chriss; Spradling, Philip; Teshale, Eyasu; Lau, Daryl; Snowball, Mary; Livingston, Stephen E.

Book ID: 121281223
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 582 KB
Volume: 12
Category: Article
ISSN: 1542-3565
DOI: 10.1016/j.cgh.2013.09.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Basal core-promoter mutant of hepatitis

Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B

✍ Chih-Lin Lin; Li-Ying Liao; Chaur-Shine Wang; Pei-Jer Chen; Ming-Yang Lai; Ding- 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Multicentre study of hepatitis B virus g

Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status

✍ P. Halfon; M. Bourlière; S. Pol; Y. Benhamou; D. Ouzan; M. Rotily; H. Khiri; C. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Early hepatitis B virus DNA reduction in

Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir

✍ Nancy Leung; Cheng-Yuan Peng; Hie-Won Hann; Jose Sollano; Judy Lao-Tan; Chao-Wei 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB 👁 2 views

This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB). Sixty-nine nucleoside-naïve CHB patients with baseline HBV DNA of 10(8) copi

Significance of hepatitis B viremia leve

Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen–negative chronic hepatitis B virus infection

✍ Emanuel K Manesis; George V Papatheodoridis; Vasilios Sevastianos; Evangelos Cho 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 71 KB

Absence of hepatitis B virus DNA detecte

Absence of hepatitis B virus DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers

✍ D.D. Douglas; H.F. Taswell; J. Rakela; D. Rabe 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 475 KB